Are you ready to seize a unique opportunity to be recognized as a supporter for finding new treatments for ARPKD? Join the PKD Foundation and the Critical Path Institute’s Polycystic Kidney Disease Outcomes Consortium (PKDOC) as a sponsor for the upcoming Externally-Led Patient Focused Drug Development Meeting (EL-PFDD) for Autosomal Recessive Polycystic Kidney Disease (ARPKD) on August 29, 2023.

Benefits include:
- Most prominent sponsor logo on meeting webpage and registration site
- Most prominent logo placement on meeting emails to prospective and confirmed attendees
- Verbal recognition, with logo, on thank you slide displayed at the start of meeting
- Verbal recognition, with logo, on thank you slide displayed during meeting breaks
- Recognition, with logo, on C-Path and PKD Foundation social media channels
- Logo placement in post-meeting Voice of the Patient Report
- Early access to post-meeting Voice of the Patient Report

Sponsorship Levels and Details

We are seeking sponsorship to ensure that patients’ experiences, perspectives, needs, and priorities are captured and meaningfully incorporated into drug development and evaluation. The funds will be used to cover the cost of hosting the EL-PFDD meeting and developing a Voice of the Patient post-meeting report. Sponsorships and associated benefits will be based upon the level of contribution: Impact Champion, Innovation Champion, and Inspiration Champion.

IMPACT CHAMPION
Exclusive Opportunities for Sponsorship of $20,000

Externally led patient-focused drug development (EL-PFDD) meetings bring together patients and care partners, US Food and Drug Administration (FDA) representatives, pharmaceutical companies, physicians, and researchers who are experts in a particular disease. The goal of this meeting is to hear directly from patients, their families, caregivers, and patient advocates about what it's like to live with ARPKD, so the FDA and pharmaceutical companies can better understand the patient experience. This patient input can help the FDA make informed decisions on approvals of potential therapies for ARPKD, and pharmaceutical companies to develop medicines and clinical trials that are meaningful for patients.
Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Amsterdam, Netherlands, with additional staff in multiple other locations. For more information, visit c-path.org and c-path.eu.

About the PKD Foundation

The PKD Foundation is the only organization in the U.S. solely dedicated to finding treatments and a cure for polycystic kidney disease (PKD). We fund research, education, advocacy, support, and awareness on a national and local level. Since 1982, we have proudly funded more than 1,300 research projects and leveraged $1.5B in research funds, making us the largest private funder of PKD research. We fund basic and clinical research, nephrology fellowships, and scientific meetings with a simple goal: to discover and deliver treatments and a cure for PKD. For more information, visit pkdcure.org.

About Critical Path Institute

Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Amsterdam, Netherlands, with additional staff in multiple other locations. For more information, visit c-path.org and c-path.eu.